Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present AB Science, Paris (OTC: ABSCF).

Full DD Report for ABSCF

You must become a subscriber to view this report.

Recent News from (OTC: ABSCF)

European advisory group April meeting results
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded its April meeting . More news on: Portola Pharmaceuticals, Radius Health, Inc., AB Science, Paris, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: April, 27 2018 10:34
3 Things In Biotech, April 22: All These 'A' Companies
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a...
Source: SeekingAlpha
Date: April, 23 2018 09:04
3 Things In Biotech You Should Learn Today: September 17, 2017
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Pfizer ODAC meeting in earlier stage kidney cancer coming up! At the moment, Pfizer's (PFE)...
Source: SeekingAlpha
Date: September, 17 2017 08:00
Deciphera Pharmaceuticals Seeks $100 Million IPO
Quick Take Waltham, Massachusetts-based Deciphera Pharmaceuticals ( DCPH ), an anti-cancer drug company, intends to raise $100 million in gross proceeds from an IPO of its common stock. Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical firm that focuses on kinase inhibi...
Source: SeekingAlpha
Date: September, 07 2017 09:38
European advisory committee rejects AB Science's masitinib marketing application for mastocytosis; shares down 26%
The European Medicines Agency's Committee for Medicinal Products for Human Use ( CHMP ) adopts a negative opinion regarding AB Sciences' ( OTCPK:ABSCF -26.3% ) marketing application seeking approval of masitinib for the treatment of adult patients with smoldering or indolent systemic sev...
Source: SeekingAlpha
Date: May, 17 2017 13:36
3 Things In Biotech You Should Learn Today: May 14, 2017
Welcome to another edition of "3 Things in Biotech You Should Learn Today," a daily digest of news from the biotech world to help you come to grips with the wide world of scientific industry. Without further ado... Biogen's partner gets on track with gene therapy for retinitis pigmentosa ...
Source: SeekingAlpha
Date: May, 14 2017 06:00
Mitsubishi Bags ALS Approval Without Radical Benefit
Amyotrophic lateral sclerosis ((ALS)) patients will no doubt be relieved to have a new option after the FDA approved Mitsubishi Tanabe Pharma's edaravone, known in the US as Radicava. But with a $145,000-per-year price tag and no proof yet that it improves survival, getting it paid for might b...
Source: SeekingAlpha
Date: May, 09 2017 07:55
FDA approves first U.S. ALS treatment in 20 years
The FDA has approved the first treatment for amyotrophic lateral sclerosis -- "Lou Gehrig's disease" -- in more than two decades in the U.S. More news on: Mitsubishi Tanabe Pharma Corp. ADR, AB Science, Paris, Cytokinetics, Incorporated, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 05 2017 17:32
Collaborative Leukemia Trial Orbits Moonshot Initiative
The once-neglected blood cancer acute myeloid leukemia has seen a flurry of activity of late – which might explain why four companies with mid-stage projects are taking the unusual step of getting involved in a collaborative study. The Beat AML trial, led by the US Leukemia & Ly...
Source: SeekingAlpha
Date: October, 20 2016 13:53
AB Science Claims A Positive Result In Masitinib ALS Study
France’s AB Science (ABSCF) seems to have notched up an unexpected positive interim readout in a phase III study with its c-KIT inhibitor, masitinib, in the difficult indication of amyotrophic lateral sclerosis (ALS). The result could represent the first progress in the ALS field in mor...
Source: SeekingAlpha
Date: April, 19 2016 14:07


About AB Science, Paris (OTC: ABSCF)

Logo for AB Science, Paris (OTC: ABSCF)

AB Science was founded in by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. We are innovators and scientific entrepreneurs in the field of life science.


Contact Information



Current Management

  • Alain Moussy / CEO, Founder
    • ngineer ENSTA , and MBA Wharton. Former strategic consultant at Booz, Allen amp Hamilton and former head of Corporate Development at Carrefour. President of AFIRMM, association of mastocytosis patients.

Current Share Structure

  • Market Cap: $379,333,185 - 03/16/2018
  • Issue and Outstanding: 31,349,850 - 07/14/2011


Daily Technical Chart for (OTC: ABSCF)

Daily Technical Chart for (OTC: ABSCF)

Stay tuned for daily updates and more on (OTC: ABSCF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ABSCF)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

The Subway Trader



Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ABSCF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of ABSCF and does not buy, sell, or trade any shares of ABSCF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: